{"schema_version":"secwatch.filing_event.v1","accession":"0001851734-22-000663","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.517522+00:00","generated_at":"2026-06-21T22:39:41.065884+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vistagen Q2 net loss $17.5M; PALISADE-2 restart after interim analysis","bullets":["Net loss $17.5M vs $13.2M YoY; R&D spend $12.9M (+$2.9M) on PH94B/PH10 trials.","Cash and equivalents $35.3M; shares outstanding 206.8M as of Nov 9, 2022.","Independent interim analysis recommends continuing PALISADE-2 Phase 3 PH94B trial; restart preparations underway.","Preliminary PALISADE Open Label data (n≈400) shows LSAS functional improvement; full assessment Q1 2023.","IND submitted to FDA for PH10 Phase 1 study in healthy volunteers to enable Phase 2B in major depressive disorder."],"urls":{"canonical":"https://secwatch.observer/filing/0001851734-22-000663","json":"https://secwatch.observer/filing/0001851734-22-000663.json","markdown":"https://secwatch.observer/filing/0001851734-22-000663.md","text":"https://secwatch.observer/filing/0001851734-22-000663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000663/0001851734-22-000663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000663/vtgn20221110_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:39:41.065884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c99b26172e4851340a1802a8e132510858a3e75a","claim":"Vistagen Therapeutics, Inc. reported financial results for its fiscal year 2023 second quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2023 second quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000663/0001851734-22-000663-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its fiscal year 2023 second quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}